Class IITerminated

Rifampin Capsules USP 150mg recall

FDA recall D-0283-2024 · initiated Jan 5, 2024

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Subpotent Drug and Failed Impurities/Degradation Specifications

Details

Product: Rifampin Capsules USP 150mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured Lupin Limited, Aurangabad 431 210 INDIA, NDC 68180-658-06
Recalling company: Lupin Pharms
Classification: Class II
Status: Terminated
Type: Voluntary: Firm initiated
Distribution: Product was distributed to 32 Wholesale/distributor accounts who further distributed the product to 156 distribution sites.
Initiated: Jan 5, 2024
FDA report date: Feb 7, 2024

What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Source: openFDA Drug Enforcement record D-0283-2024 ↗

← All drug recalls